P53 and Tumor Suppression
Overview
Authors
Affiliations
Erdogan M, Ozer G Pharmaceuticals (Basel). 2025; 18(2).
PMID: 40006067 PMC: 11859711. DOI: 10.3390/ph18020254.
Koutb F, Abdel-Rahman S, Hassona E, Haggag A Asian Pac J Cancer Prev. 2017; 18(8):2049-2057.
PMID: 28843220 PMC: 5697458. DOI: 10.22034/APJCP.2017.18.8.2049.
Molecular driver alterations and their clinical relevance in cancer of unknown primary site.
Loffler H, Pfarr N, Kriegsmann M, Endris V, Hielscher T, Lohneis P Oncotarget. 2016; 7(28):44322-44329.
PMID: 27322425 PMC: 5190099. DOI: 10.18632/oncotarget.10035.
L-GILZ binds p53 and MDM2 and suppresses tumor growth through p53 activation in human cancer cells.
Ayroldi E, Petrillo M, Bastianelli A, Marchetti M, Ronchetti S, Nocentini G Cell Death Differ. 2014; 22(1):118-30.
PMID: 25168242 PMC: 4262776. DOI: 10.1038/cdd.2014.129.
Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients.
Liu J, Mao Q, Liu Y, Hao X, Zhang S, Zhang J Chin J Cancer Res. 2013; 25(1):46-54.
PMID: 23372341 PMC: 3555294. DOI: 10.3978/j.issn.1000-9604.2012.11.04.